Costs of uncontrolled chemotherapy-induced nausea and vomiting among working-age cancer patients receiving highly or moderately emetogenic chemotherapy
- PMID: 17567835
- DOI: 10.1002/cncr.22823
Costs of uncontrolled chemotherapy-induced nausea and vomiting among working-age cancer patients receiving highly or moderately emetogenic chemotherapy
Abstract
Background: Chemotherapy-induced nausea and vomiting (CINV) is among the most feared side effects of cancer treatment. Poorly controlled CINV may lead to additional office visits or emergency room admissions, thus increasing the overall costs of cancer care. The objective of the project was to estimate the societal costs of uncontrolled CINV among working-age cancer patients.
Methods: The 1997-2002 Health and Productivity Management database, a proprietary database linking medical claims to work loss information, was used. The study population consisted of employees or their spouses who were cancer patients treated with highly or moderately emetogenic chemotherapy regimens. Costs of uncontrolled CINV were estimated by comparing the direct medical costs and indirect costs between those with and without uncontrolled CINV; all costs were normalized as monthly costs and updated to 2006 US dollars. The Wilcoxon Mann-Whitney test was used to compare the costs differences in univariate analyses, followed by multivariate analyses.
Results: In all, 2,018 patients were identified; 1,771 (88%) received 5-HT(3) receptor antagonists, and uncontrolled CINV was found in 563 (28%). The estimated monthly medical costs associated with uncontrolled CINV were approximately 1,300 dollars higher for cancer patients at working ages. Subgroup analysis concluded that indirect costs per patient per month were 433 dollars higher for those in the uncontrolled CINV group.
Conclusions: Despite a prevalent use of the 5-HT(3) receptor antagonists, uncontrolled CINV remained a common and costly problem among cancer patients treated with highly or moderately emetogenic chemotherapy.
(c) 2007 American Cancer Society.
Similar articles
-
Palonosetron versus other 5-HT(3) receptor antagonists for prevention of chemotherapy-induced nausea and vomiting in patients with cancer on chemotherapy in a hospital outpatient setting.Clin Ther. 2011 Apr;33(4):443-55. doi: 10.1016/j.clinthera.2011.04.009. Clin Ther. 2011. PMID: 21635990
-
Cost-effectiveness of aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with highly emetogenic chemotherapy.Value Health. 2007 Jan-Feb;10(1):23-31. doi: 10.1111/j.1524-4733.2006.00141.x. Value Health. 2007. PMID: 17261113
-
Impact of 5-HT(3) RA selection within triple antiemetic regimens on uncontrolled highly emetogenic chemotherapy-induced nausea/vomiting.Expert Rev Pharmacoecon Outcomes Res. 2011 Aug;11(4):481-8. doi: 10.1586/erp.11.47. Epub 2011 Jun 28. Expert Rev Pharmacoecon Outcomes Res. 2011. PMID: 21711119
-
Chemotherapy-induced nausea and vomiting.Cancer J. 2008 Mar-Apr;14(2):85-93. doi: 10.1097/PPO.0b013e31816a0f07. Cancer J. 2008. PMID: 18391612 Review.
-
Aprepitant: a neurokinin-1 receptor antagonist for the treatment of chemotherapy-induced nausea and vomiting.Expert Rev Anticancer Ther. 2004 Oct;4(5):715-24. doi: 10.1586/14737140.4.5.715. Expert Rev Anticancer Ther. 2004. PMID: 15485308 Review.
Cited by
-
A nonparametric statistical method that improves physician cost of care analysis.Health Serv Res. 2012 Dec;47(6):2398-417. doi: 10.1111/j.1475-6773.2012.01415.x. Epub 2012 Apr 23. Health Serv Res. 2012. PMID: 22524195 Free PMC article.
-
Metagenomics and chemotherapy-induced nausea: A roadmap for future research.Cancer. 2022 Feb 1;128(3):461-470. doi: 10.1002/cncr.33892. Epub 2021 Oct 13. Cancer. 2022. PMID: 34643945 Free PMC article. Review.
-
Use and cardiovascular safety of transdermal and other granisetron preparations in cancer management.Cancer Manag Res. 2013 Jul 29;5:179-85. doi: 10.2147/CMAR.S34352. Print 2013. Cancer Manag Res. 2013. PMID: 23930078 Free PMC article.
-
Work loss and activity impairment due to extended nausea and vomiting in patients with breast cancer receiving CINV prophylaxis.Support Care Cancer. 2023 Oct 25;31(12):654. doi: 10.1007/s00520-023-08119-1. Support Care Cancer. 2023. PMID: 37878086 Free PMC article.
-
Palonosetron in the management of chemotherapy-induced nausea and vomiting in patients receiving multiple-day chemotherapy.Cancer Manag Res. 2014 Sep 5;6:329-37. doi: 10.2147/CMAR.S68102. eCollection 2014. Cancer Manag Res. 2014. PMID: 25228819 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical